No Data
Nanjing Vishee Medical Technology Co., Ltd (688580.SH): plans to launch a restricted stock incentive plan in 2025.
On April 25, Glonghui reported that Nanjing Vishee Medical Technology Co., Ltd (688580.SH) announced its 2025 Restricted Stock Incentive Plan, in which the number of restricted stocks proposed to be granted to the incentive recipients is 1 million shares, accounting for approximately 1.04% of the company's total share capital of 95.771288 million shares as of the announcement date of this incentive plan draft. Among them, the initial grant of restricted stocks is 0.904 million shares, accounting for about 0.94% of the company's total share capital of 95.771288 million shares as of the announcement date of this incentive plan draft, and representing 90.40% of the total number of restricted stocks to be granted under this incentive plan; reserving 9.60.
Nanjing Vishee Medical Technology Co., Ltd (688580.SH): The net income for 2024 is 0.102 billion yuan, a decrease of 25.16% year-on-year.
Gelonghui reported on April 25 that Nanjing Vishee Medical Technology Co., Ltd (688580.SH) announced that it achieved revenue of 0.4 billion yuan in 2024, a decrease of 13.45% year-on-year; the Net income attributable to shareholders of the listed company was 0.102 billion yuan, a decrease of 25.16% year-on-year; the basic EPS was 1.0685 yuan. The company plans to distribute a cash dividend of 8 yuan (tax included) for every 10 shares to all shareholders.
Weiss Healthcare: Nanjing Weisi Medical Technology Co., Ltd. Report for the first quarter of 2025
Weiss Healthcare: Nanjing Weisi Medical Technology Co., Ltd. 2024 Annual Report
Weiss Healthcare: Summary of the 2024 Annual Report of Nanjing Weisi Medical Technology Co., Ltd.
Nanjing Weisi Medical Technology Co., Ltd. 2024 Annual Report
Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) 26% Dip In Price Shows Sentiment Is Matching Earnings
